181 related articles for article (PubMed ID: 14981183)
1. Liver injury associated with the beta-interferons for MS: a comparison between the three products.
Tremlett HL; Yoshida EM; Oger J
Neurology; 2004 Feb; 62(4):628-31. PubMed ID: 14981183
[TBL] [Abstract][Full Text] [Related]
2. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
3. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
4. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
5. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Tamura S; Warabi Y; Matsubara S
J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
[TBL] [Abstract][Full Text] [Related]
6. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
7. Liver injury associated with the beta-interferons for MS.
Francis GS; Kaplowitz N; Alteri E
Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
[No Abstract] [Full Text] [Related]
8. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
9. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
[TBL] [Abstract][Full Text] [Related]
11. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
14. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
15. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
16. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.
Tremlett H; Oger J
J Neurol; 2004 Nov; 251(11):1297-303. PubMed ID: 15592724
[TBL] [Abstract][Full Text] [Related]
17. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.
Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H
Expert Opin Drug Saf; 2014 Oct; 13(10):1305-17. PubMed ID: 25134421
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
[TBL] [Abstract][Full Text] [Related]
19. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
[TBL] [Abstract][Full Text] [Related]
20. Patient page. Multiple sclerosis treatment: some safety issues to keep in mind.
Aguilar M
Neurology; 2004 Feb; 62(4):E8-9. PubMed ID: 14981207
[No Abstract] [Full Text] [Related]
[Next] [New Search]
